16 Apr DDW: 2024 predictions: Experts weigh in on stem cells
DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on the future of stem cells in drug discovery.
Author: equipe
16 Apr EUROPEAN PHARMACEUTICAL MANUFACTURER: Optimising TIME-TO-MARKET for innovative cell therapy
Didier HAGUENAUER - CMO - CELLPROTHERA
29 Feb CellProthera collaborates with Japanese stem cell experts at Shonan-Kamakura General Hospital (SKGH) on clinical manufacturing for upcoming autologous stem cell trials in ischemic diseases
- Upcoming clinical trials, led by stem cell pioneer Professor Takayuki Asahara, will use CellProthera’s StemXpand® and StemPack® technology to manufacture endothelial progenitor cells (EPCs)
- This collaboration is the first to bring CellProthera’s manufacturing systems to Japan, following successful use of the systems in clinical trials in Europe
29 Feb PHARMIWEB: CellProthera collaborates with Japanese stem cell experts…
CellProthera collaborates with Japanese stem cell experts at Shonan-Kamakura General Hospital (SKGH) on clinical manufacturing for upcoming autologous stem cell trials in ischemic diseases
10 Nov LE FIGARO | DOSSIER SANTE – Stem cells : a promise that is becoming a reality
A 20 year old promise slowly becoming a reality
07 Nov CVCT-CardioVascular Clinical Trialists Washington DC 30 Nov-2 Dec
CellProthera will participate in the Global CardioVascular Clinical Trialists Forum (CVCT) on November 30 - December 2nd,...
04 Oct University Hospitals Birmingham Connected: Heart patient given new lease of life
Kim Smith, a 66-year-old heart attack patient, experienced a life-changing breaktrough after receiving stem cell therapy at Queen Elizabeth Hospital Birmingham (QEHB)
26 Sep PHARMIWEB: CellProthera completes enrollment in Phase I/IIB trial for post-myocardial infarction cell therapy
Final patient receives ProtheraCytes(R) cell therapy to regenerate damaged heart tissue following severe heart attack. Study remains on track for final readout in H1 2024
26 Sep CellProthera completes enrollment in Phase I/IIB trial for post-myocardial infarction cell therapy
- Final patient receives ProtheraCytes® cell therapy to regenerate damaged heart tissue following severe heart attack
- Study remains on track for final readout in H1 2024
31 Jul DDW – Turning science into business: Can regenerative medicine treat heart attacks?
DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.